This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

The Clinical Trials Industry’s Weekly News Update

‘New’ CRO PoraGene to target drug and gene therapy sector

Share this article

Newly rebranded CRO ProtaGene has set out to establish itself as a full-service partner for biopharmaceutical and gene therapy developers.

The German-American firm – which was formed last year through the merger of Protagen Protein Services, BioAnalytix and GeneWerk – relaunched this week, stating its aim is to offer a complete range biopharmaceutical and gene therapy development service.

The organization has a team of more than 175 employees across four laboratory and technical sites in Europe and North America.

ProtaGene CEO Martin Blüggel cited the experience the constituent companies’ experience as the new firms defining characteristic.

“The track record and reputation of the three legacy entities are individually impressive, and their combination into a single, globally integrated business delivers significant compounded value for our sponsors.

“Our new scale and breadth of expertise will benefit the impressive list of innovative products we support, both in development and on the market, and ultimately deliver for patients worldwide.

He added, “We are passionate in our vision to establish ProtaGene as the world’s leading CRO partner in biologics and cell & gene therapy markets.”

Merger

ProtaGene is owned by Boston, US-based private equity investor Ampersand Capital Partners, which bought GeneWerk in 2020. Ampersand bought Protagen Protein Services – through GeneWerk – last July.

PPS which was previously owned by German venture capital firm Zukunftsfond Heilbronn, originally merged with US analytical services company BioAnalytix in a deal completed in 2019.

GeneWerk offers a range of vector safety, characterization, and functionality analysis services, while PPS provides analytical testing protein characterization identity, purity, potency and capsid loading.

Ampersand announced plans to bring PPS and GeneWerk together last July, adding that it planned to significantly expand US laboratory capabilities in order to better serve clients located in the Boston area biotechnology hub and elsewhere in North America.

Image: Stock Photo Secrets

Share this article

Sign up for Clinical Insider email updates